ITI Pharma and Healthcare Fund - Regular Plan - Growth
ITI Asset Management Limited
₹17.28 (+0.65%)
NAV as of 9 Oct 2026
Minimum Investment: ₹5,000
Return
6.29% Returns for 1Y
Expense ratio & Others
- Net expense ratio
- 2.35%
- Exit load
- 0%
- Lock-in
- No
- Minimum investment
- ₹5,000
- Category
- Sector - Healthcare
Expense ratio is inclusive of GST. Returns may be taxed based on the fund type and your holding period — please read the scheme-related documents and consult a tax advisor. Figures are historical and do not guarantee future results.
Fund Returns Estimator
One-time investment
₹1,000
6 months
₹1,146
Invested ₹1,000
▲+14.65%1 year
₹1,063
Invested ₹1,000
▲+6.29%3 years
₹1,166
Invested ₹1,000
▲+16.55%
Based on the fund’s historic trailing returns — a planning illustration, not a guarantee of future results.
Invest One-TimePlan it your way
The figures above are fixed to this fund’s past returns over set periods. Use a calculator to set your own amount, tenure and expected rate of return.
Risk level
Riskometer scale
- Low
- Low to Moderate
- Moderate
- Moderate to High
- High
- Very HighThis fund
Riskometer level assigned by the fund house as per SEBI norms. It can change as the scheme’s portfolio changes.
Fund benchmark
| Primary Index Name | BSE Healthcare PR INR |
|---|---|
| Secondary Index Name | BSE Healthcare PR INR |
| Index Name | Nifty Healthcare TR INR |
| Weighting | 100% |
Returns
| 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|
| Fund returns (%) | +6.29% | +16.55% | — | — |
| Cumulative returns (%) | +6.29% | +58.33% | — | — |
Fund Manager
| Manager | Animesh Singh |
|---|---|
| Role | Manager |
| Manager Tenure | 0.4 yrs |
About Fund
| Date of Incorporation | 11 Nov 2021 |
|---|---|
| Fund House | ITI Asset Management Limited |
| Custodian | Deutsche Bank AG |
| Registrar / Transfer Agent | ITI Asset Management Limited |
| Address | 1 Great Winchester Street |
Top Holdings
| Company | Weightage (%) |
|---|---|
| Sun Pharmaceuticals Industries Ltd | 12.58% |
| Divi's Laboratories Ltd | 9.23% |
| Apollo Hospitals Enterprise Ltd | 5.72% |
| Max Healthcare Institute Ltd Ordinary Shares | 4.84% |
| Torrent Pharmaceuticals Ltd | 4.75% |
| Dr Reddy's Laboratories Ltd | 4.31% |
| Cipla Ltd | 4.22% |
| Laurus Labs Ltd | 4.02% |
| Aurobindo Pharma Ltd | 3.97% |
| Mankind Pharma Ltd | 3.31% |
| Lupin Ltd | 3.30% |
| Aster DM Healthcare Ltd Ordinary Shares | 3.16% |
| Alkem Laboratories Ltd | 3.12% |
| Fortis Healthcare Ltd | 3.11% |
| Cohance Lifesciences Ltd | 3.08% |
Investment Strategy
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Capital appreciation over long term
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. The data shown is for information only and does not constitute investment advice.